Key result
Intravenous milrinone significantly decreased left ventricular end-diastolic pressure (from 27 to 18 mm Hg) and increased cardiac index (from 1.9 to 2.9 L/min/m2) in severe congestive heart failure.
Why the study?
Does milrinone improve hemodynamics and symptoms in patients with severe congestive heart failure?
Population
20 patients with severe congestive heart failure
Design
Case_series
Follow-up
up to 11 months (mean 6.0 +/- 0.8 months)
Authors
Loading...
May support acute hemodynamic benefit of milrinone in severe CHF; hypothesis-generating and requires controlled trials before practice change.
Observational (n=20)
Does milrinone improve hemodynamics and symptoms in patients with severe congestive heart failure?
Milrinone provides sustained hemodynamic and symptomatic improvement in patients with severe congestive heart failure without causing fever or thrombocytopenia.
Baim et al. (1983) conducted an observational in Severe congestive heart failure (n=20). Milrinone was evaluated on Hemodynamic parameters including left ventricular end-diastolic pressure and cardiac index. Intravenous milrinone significantly decreased left ventricular end-diastolic pressure (from 27 to 18 mm Hg) and increased cardiac index (from 1.9 to 2.9 L/min/m2) in severe congestive heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: